News

The phase 3 Keynote-061 trial assessing Keytruda as a second-line treatment for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma did not achieve its primary endpoint of

The drug-discovery partnership, which will last for five-years, will be focused on Messenger RNA (mRNA) translation. According to Cancer Research UK, mRNA translation, which is the cellular process of assembling proteins,

Actus will benefit from AskBio’s ability to generate organ and tissue-specific single-stranded and self-complementary genome containing adeno-associated virus vectors (AAVs), the company’s manufacturing platform and managements’ experience progressing

XELJANZ/XELJANZ XR is the first and only Janus kinase (JAK) inhibitor approved by the FDA for both moderate to severe rheumatoid arthritis (RA) and active PsA. “Psoriatic arthritis

The reductions in jobs, which will be carried out over the next two years, represent over 25% of the company's total workforce. Teva’s restructuring plan aims to cut down

As part of the agreement, Flexion obtained an exclusive license to the underlying intellectual property rights for human use of GQ-203 from Baylor College of Medicine. GQ-203, now

As a result, GW has now reacquired full ownership of the development and commercialization rights to the product in the U.S. market without making any upfront payment to

IXIFI is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor. The drug has now been indicated in the US for the treatment of patients having rheumatoid

The Company’s Board of Directors has unanimously approved the transaction.   Under the terms of the merger agreement, a subsidiary of Allergan will commence a cash tender offer to